Boston Scientific Strategies to Counter Market Share Erosion in 2026

Boston Scientific’s approach to market share erosion in PFA and EP markets in 2026

Boston Scientific is acknowledging increased competitive intensity that should lead to more share erosion than it previously expected, but management is framing 2026 as a year of disciplined execution to hold onto PFA leadership while accelerating platform/product refreshes that they believe will protect share into the longer run. ¹²

1) Management explicitly guides for “more share erosion” in 2026, while still targeting leadership

• Management says it expects “a little bit more share erosion than we’ve anticipated” and describes this as reflected in updated guidance, while stating the company still aims to maintain PFA market leadership in the U.S., internationally, globally in 2026, and throughout the LRP. ¹
• In the EP discussion, management reiterates confidence in remaining a PFA market leader in the U.S. and globally in 2026, even while acknowledging competitive pressures. ²

How that addresses erosion: rather than trying to “deny” erosion, BSX is building 2026 plans around the expectation of some share loss, while focusing investments and product/platform actions intended to prevent leadership from slipping. ¹²

2) Increased competitive pressure is the core reason share erosion is becoming more likely

Management points to a more competitive setup in the PFA market:

• They cite “three other large players” in the marketplace, with specific competitive commentary that Medtronic remains a solid competitor, J&J is enhancing its footprint in PFA, and Abbott is in the early stages of launch in the U.S. ¹
• They also connect share erosion expectations to “ongoing competitive dynamics,” with guidance for EP/PFA adjusted accordingly. ³

How that addresses erosion: BSX is treating erosion as competition-driven (not demand-driven), and is responding with commercialization and platform investments (below), rather than relying solely on market growth. ¹³

3) Commercial and marketing investment is part of the countermeasure (especially for EP/PFA and WATCHMAN)

On the commercial side, management emphasizes both targeted investment and marketing support:

• BSX says it has made a “massive investment” in mapping platforms and commercial capabilities, including installing more OPAL mapping platforms, increasing map sophistication, and adding new catheters like FARAPOINT (recently launched). ⁴
• They also say they will keep investing in commercial capabilities across WATCHMAN and EP businesses (explicitly including both WATCHMAN and EP businesses). ⁴

While some of the WATCHMAN detail is adjacent to EP market dynamics, the key point is that management is emphasizing commercial investment as a lever to offset share pressure. ⁴

4) Expanding the EP/PFA technology “ecosystem” (mapping footprint + next-gen catheters) to defend share

BSX links its PFA leadership plan to strengthening its ecosystem:

• For EP specifically, management reports that international EP growth is being driven by expanded OPAL Mapping footprint in catheter utilization and cites strong double-digit PFA growth in Europe in a competitive environment, supported by the launch of FARAPOINT. ³
• Management also highlights continued strengthening of its mapping platforms (OPAL) and adding new catheters to the mix, including FARAPOINT, as part of how it expects to sustain leadership despite erosion pressures. ⁴

In addition, management highlights product launch momentum that is expected to be “disruptive” over the next couple of years (which is relevant to how they plan to slow/stop erosion after 2026):

• They discuss upcoming major product launches, including third-generation FARAPULSE and a next-generation mapping/catheter platform, and they describe these as potentially disruptive for the platform roadmap in the next ~2.5 years. ¹
• For EP planning continuity, they reference new data/programs tied to FANAFLEX and other next-gen platform elements (e.g., clinical study activity and planned launch timing). ⁵

How that addresses erosion: management’s defense is not only “commercial spend,” but also widening the platform moat (mapping + catheter portfolio) so that procedural adoption and workflow fit remain favorable even as competitors intensify. ¹⁴³

5) EP growth targets suggest BSX is still scaling—while accepting a slower competitive outcome in market share terms

Even with erosion risk, BSX is guiding meaningful EP growth:

• BSX expects global EP business to grow ~10% in 2026. ³
• Within that, management updates expected U.S. EP growth to mid-single digits, while expecting international at ~plus 20% (including an approximate $35 million impact from POLARx discontinuation). ³
• In discussing the guide change, management attributes the revised outlook to unanticipated headwinds and changing business patterns, including the competitive dynamics that are relevant to PFA share. ⁶³

How that addresses erosion: by guiding solid EP growth while explicitly expecting share pressure, BSX is effectively saying: we may lose some share, but we intend to out-execute enough on platform/procedure adoption to still grow meaningfully—especially internationally where performance is supported by mapping/catheter momentum. ¹³

---

Bottom line

In 2026, Boston Scientific is addressing PFA/EP market share erosion by (1) acknowledging increased competitive pressure and guiding for more erosion than previously expected, while (2) committing to maintain PFA leadership through investment in mapping platforms and EP commercialization, and (3) supporting share defense with its OPAL mapping footprint expansion and portfolio launches (e.g., FARAPOINT and next-generation FARAPULSE/FANAFLEX roadmap elements) that management believes will strengthen its differentiated ecosystem into and beyond 2026. ¹⁴³²